Current Naturopathy to Combat Alzheimer's Disease
Arnob Chakrovorty1, Banani Bhattacharjee1, Aaruni Saxena2
1Department of Zoology, Cytogenetics and Molecular Biology Lab., University of Kalyani, Kalyani, 741235, India.
Current Neuropharmacology
|September 29, 2022
Summary
Alzheimer's disease (AD) is a common dementia causing neuron loss. This review explores natural phytochemicals as potential treatments, possibly combining with synthetic drugs for better patient outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, affecting over 45 million people globally.
- AD's complex etiology involves genetic, neurometabolomic, and lifestyle factors, leading to neuronal death and impaired nervous system function.
- Neuropathology includes neurotransmitter deficiencies, beta-amyloid plaques, and tau tangles, posing significant challenges for current treatments.
Approach:
- This review examines promising phytochemical compounds with therapeutic potential against AD targets.
- It focuses on naturally occurring compounds as alternatives or adjuncts to synthetic drugs, addressing issues of resistance and toxicity.
- The review synthesizes current research on phytochemicals for Alzheimer's disease treatment.
Key Points:
- Phytochemicals offer a promising avenue for novel Alzheimer's disease pharmacotherapeutics.
- Natural compounds may overcome limitations of current synthetic drugs, such as toxicity and resistance.
- Targeting beta-amyloid plaques and tau tangles with phytochemicals is a key research focus.
Conclusions:
- Phytochemicals demonstrate significant potential in combating Alzheimer's disease neuropathology.
- A combination of naturopathy and synthetic chemotherapeutics may enhance patient survival and quality of life.
- Further research into phytochemical efficacy and synergistic effects is warranted for AD management.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
Related Concept Videos
01:22Alzheimer's Disease: Treatment
248
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248
01:26Alzheimer's Disease: Overview
635
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
635
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
193
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
193
01:30Dementia
159
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
159
01:24Parkinson's Disease: Treatment
354
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
354
01:26Atherosclerosis III: Management
24
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
24